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Abstract
Background: Nearly half of all patients diagnosed with multiple sclerosis (MS) will develop cognitive dysfunction.
Studies highlighted from no/weak impact to a strong impact of cognitive impairment on quality of life (QoL). The
aim of this study was to assess the impact of cognitive dysfunction on self-reported QoL in MS patients while
considering key confounding factors.
Methods: Design: cross-sectional study. Inclusion criteria: MS patients of any disease subtype. Data collection:
sociodemographic (age, gender, marital status, education level, and occupational activity) and clinical data (MS
subtype, disease duration); MS disability (Expanded Disability Status Scale, EDSS); depression (Beck Depression
Inventory); fatigue (Modified Fatigue Impact Scale); QoL (SF36 and MusiQoL); and neuropsychological performance
(Brief Repeatable Battery of Neuropsychological Tests, BRB-N). Statistical analysis: multiple linear regressions
(forward-stepwise selection).
Results: One hundred and twenty-four patients were enrolled. Performance on BRB-N subtests varied widely (6%
to 70% abnormal). The BRB-N classified 37-78% of the patients as cognitively impaired, depending on the definition
of cognitive impairment. No links were found between the MusiQoL index and cognitive subtests, whereas marital
status, EDSS, and depression were found to be independent predictive factors.
Conclusions: The present study demonstrated the weak and scarce association between cognitive impairment and
QoL, when the key confounding factors were considered. These results need to be confirmed with larger samples
and more accurate tests of cognitive function.
Background
Multiple sclerosis (MS) is the most common demyeli-
nating disease of the central nervous system in young
adults. Cognitive impairment occurs in about 50% of
patients with MS [1,2], even during the early stages of
the disease [3,4]. Cognitive dysfunction may subse-
quently result in reduced fulfilment in work life and
social life as well as in a reduction in quality of life
(QoL) [5-7]. To date, few studies have reported rela-
tionships between cognitive function and patient QoL
[8,9]. Existing studies have revealed contradictory
results, highlighting either negligible impact [7,10-13]
or a strong impact [5,14,15] of cognitive impairment
on QoL. The potential weaknesses of these studies
could lie in the cognitive or QoL evaluations. In some
studies, the cognitive assessment was restricted to a
single cognitive function [14,15]. In others, cognitive
impairment was defined using tools recognised as
insufficiently sensitive [5,12]. In still other studies, the
QoL assessment was restricted to a single QoL-specific
domain [11], or QoL predictors were not considered
simultaneously [12,14]. Thus, it was necessary to
assess the relationship between cognitive performance
and QoL using a standardised neuropsychological bat-
tery and a disease-specific patient-based instrument,
respectively. To our knowledge, only one previous
study has reported this relationship using both a well-
established battery of cognitive tests (Brief Repeatable
Battery of Neuropsychological Tests) and a well-vali-
dated QoL measure (Multiple Sclerosis Quality of Life
Inventory) [16]. However, this study focused on early
MS, and depression was the only controlled variable.
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function and QoL in a sample of patients with MS,
including any disease subtypes, while considering the
key sociodemographic and clinical confounding factors
to report that cognitively disabled patients with MS
are able to give consistent answers to self-reported
questionnaires.
Methods
This study incorporated a cross-sectional design and
was performed in the neurology department of a
French public academic teaching hospital (Marseille,
France). The inclusion criteria were as follows: MS
patients according to McDonald criteria [17,18], any
disease subtype, no history of psychiatric or neurologi-
cal disease (other than MS), no history of alcohol/drug
abuse, and native French speakers. The French Ethics
Committee (Comité de Protection des Personnes, Mar-
seille II) approved the study, and patients gave their
informed consent to participate. Sociodemographic
(age, gender, marital status, education level, and occu-
pational activity) and clinical (MS subtype, disease
duration) data were recorded. The MS disability was
assessed using the Expanded Disability Status Scale
(EDSS). Depression was assessed using the self-admi-
nistered Beck Depression Inventory (BDI) [19], and
fatigue was assessed using the 21-item Modified Fati-
g u eI m p a c tS c a l e( M F I S )[ 2 0 ] .
Two QoL questionnaires were administered. The
Short Form 36 (SF36) is a generic questionnaire [21]
describing eight subscales (physical function, social func-
tioning, role physical, role emotional, mental health,
vitality, bodily pain, and general health). Two composite
scores (physical and mental, PCS-SF36 and MCS-SF36)
can also be calculated. The Multiple Sclerosis Interna-
tional Quality of Life (MusiQoL) is a well-validated, dis-
ease-specific questionnaire [22] describing nine
dimensions (activity of daily living (ADL), psychological
well-being (PWB), symptoms (SPT), relationships with
friends (RFr), relationships with family (RFa), relation-
ships with health care system (RHCS), sentimental and
sexual life (SSL), coping (COP), and rejection (REJ)) and
yielding a global index score.
Neuropsychological performance was assessed using
the Brief Repeatable Battery of Neuropsychological Tests
(BRB-N) [23]. The eight subtests were selected to
explore most of the cognitive functions: the three
indices of the Selective Reminding Test (SRT-L, SRT-C,
SRT-D), a verbal learning/memory test; the two indices
of the 10/36 Spatial Recall Test (SPART-T, SPART-D),
a visuospatial learning and memory test; the Symbol
Digit Modalities Test (SDMT), which determines the
speed of visual information processing, complex visual
scanning, and sustained attention; the Paced Auditory
Serial Addition Test (PASAT-3), involving mental calcu-
lation, working memory, concentration, and information
processing speed; and the Word List Generation test
(WLG), a semantic verbal fluency test. The battery was
administered in a standardised way by the same psychol-
ogist (FR), who was intensively trained in test adminis-
tration. Cognitive impairment or deficit was defined
using Camp’s normative values [24]. The subject was
considered cognitively impaired or deficient for one
subtest if the score was at least two SDs below the
mean normative values, and he/she was considered cog-
nitively impaired or deficient for the global battery if he/
she was cognitively impaired for at least three of the
eight subtests.
Statistical analyses
Data were expressed as the means/standard deviations
or the medians/ranges, depending on the parametric or
non-parametric distribution of the variable. Associations
between the QoL scores and continuous variables (fati-
g u e ,d e p r e s s i o n ,B R B - Ns u b t e s t s ,a g e ,E D S S ,d i s e a s e
duration) were analysed using Spearman’s correlation
tests. Means-based comparisons of the MusiQoL dimen-
sions and the indices between different sub-groups (gen-
der, educational level, marital status, living, occupational
status, MS subtype, BRB-N cognitive function) were cal-
culated using Mann-Whitney or Kruskal-Wallis tests.
To determine variables potentially predictive QoL levels,
multiple linear regressions (forward-stepwise selection)
were performed. The MusiQoL index and each of the
MusiQoL dimensions were considered as separate
dependent variables. The variables relevant to the mod-
els were selected from the univariate MusiQoL index
analysis, based on a threshold p-value ≤0.20 (MFIS-To,
BDI) or a threshold p-value ≤0.30 for the BRB-N subt-
ests. A set of additional variables was included in the
models owing to their clinical and sociodemographic
relevance (gender, age, marital status, EDSS, MS
subtype, and disease duration). The final models incor-
porated the standardised beta coefficients. The indepen-
dent variables with the higher standardised beta
coefficients are those with a greater relative effect on
QoL. The statistical analyses were performed using the
SPSS software package version 15.0 (SPSS Inc., Chicago,
IL, USA). All tests were two-sided. Statistical signifi-
cance was defined as p < 0.05.
Results
One hundred and twenty-four consecutive inpatients and
outpatients with MS were enrolled during a twelve-month
period. The mean age was 45.05 years (SD 10.80), the sex-
ratio was 0.75, 47.2% were single, 47.2% had more than
12 years of education, 64.5% were unemployed, and
87.3% were living in a personal home. The MS subtypes
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20 primary progressive, and 7 clinically isolated
syndromes. Performance on BRB-N subtests varied
widely (6% to 70% abnormal). The BRB-N classified 37-
78% of the patients as cognitively impaired, depending on
the definition of cognitive impairment. The clinical
features, self-reported data, and cognitive data are listed in
table 1.
The QoL was not strongly associated with any cogni-
tive subtests. The MusiQoL index was not significantly
correlated with the BRB-N subtests. Weakly significant
correlations were identified for the ADL, SPT, RFa, and
Table 1 Clinical characteristics, self-reported quality of life and cognitive functions
N = 124
Disease duration in years median [range] 9.86 [0-31.00]
EDSS
a median [range] 4.75 [1.00-8.00]
Depression BDI
b (0-39) 10.42 ± 5.77
BDI
b classes (moderate/severe depression) 47 (70.1%)
Fatigue MFIS
c Physical (0-36) 25.97 ± 7.27
MFIS
c Cognitive (0-40) 18.75 ± 8.87
MFIS
c Psychosocial (0-8) 5.35 ± 2.07
MFIS
c Total (0-84) 50.03 ± 15.31
SF36
d Physical function (0-100) 33.88 ± 26.78
Social functioning (0-100) 50.88 ± 23.09
Role physical (0-100) 20.95 ± 30.62
Role emotional (0-100) 32.28 ± 38.16
Mental health (0-100) 49.90 ± 17.81
Vitality (0-100) 32.48 ± 19.12
Body pain (0-100) 45.80 ± 26.21
General health (0-100) 39.72 ± 20.28
Mental composite score 32.64 ± 8.83
Physical composite score 38.59 ± 9.53
MusiQoL
e Activity of daily living (0-100) 29.94 ± 21.24
Psychological well-being (0-100) 50.97 ± 24.79
Relationships with friends (0-100) 62.03 ± 24.21
Symptoms (0-100) 54.31 ± 23.85
Relationships with family (0-100) 72.17 ± 24.89
Relationships with health care system (0-100) 69.49 ± 19.48
Sentimental and sexual life (0-100) 49.19 ± 31.75
Coping (0-100) 55.64 ± 29.40
Rejection (0-100) 66.00 ± 33.42
Index (0-100) 56.63 ± 12.57
BRB-N subtests
f SRT-L
g 46.44 ± 15.27
SRT-C
g 40.17 ± 15.72
SRT-D
g 9.37 ± 2.96
SPART-T
g 16.40 ± 5.20
SPART-D
g 5.29 ± 2.36
SDMT
g 35.68 ± 11.92
PASAT-3
g 34.15 ± 15.02
WLG
g 25.32 ± 8.40
aEDSS Expanded Disability Status Scale; the higher the score, the more severe the disability.
bBDI Beck Depression Inventory; the higher the score, the worse the depression.
cMFIS Modified Fatigue Impact Scale; the higher the score, the more severe the fatigue.
dSF36 Short Form 36; the higher the score, the higher the QoL level.
eMusiQoL Multiple Sclerosis International Quality of Life; the higher the score, the higher the QoL level.
fBRB-N subtests; the higher the score, the higher the cognitive performance.
gSRT-L Selective Reminding Test Long-term, SRT-C Selective Reminding Test Consistent long-term, SRT-D Selective Reminding Test Delayed, SPART-T SPAtial
Recall Test Total, SPART-D SPAtial Recall Test Delayed, SDMT Symbol Digit Modalities Test, PASAT-3 Paced Auditory Serial Addition Test 3 s, WLG Word List
Generation test.
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mance given a higher QoL level, and for the REJ dimen-
sion, indicating a higher cognitive performance given a
lower QoL level. Depression and fatigue (with the
exception of the physical component) were significantly
linked to the MusiQoL index and the two composite
scores of the SF36. All correlations are presented in
table 2.
The MusiQoL index was not statistically linked to the
sociodemographic/clinical status, except in the case of
marital status; single patients had lower QoL scores.
Relationships between the MusiQoL dimensions and
sociodemographic/clinical variables are detailed in table 3.
The variables selected for the multivariate models included
gender, marital status, age, EDSS, MS subtype, disease
d u r a t i o n ,M F I S - T o ,B D I ,a n dt h ef o u rs u b t e s t sw i t h
p-value ≤0.30 (SRT-L, SRT-D, SPART-T, WLG). No asso-
ciations were found between the MusiQoL index and the
cognitive subtests. Marital status, EDSS, and depression
were associated with the MusiQoL index. No links
between the MusiQoL dimensions and cognitive functions
were identified, except in the case of SPART-T with
RHCS. The QoL dimensions describing physical compo-
nents, such as ADL and SPT, were related to depression
and fatigue, respectively. The dimensions describing
relationship aspects, such as RFr and RFa, were linked to
gender and marital status, respectively. These results are
summarised in table 4.
Discussion
In the last few decades, there has been considerable
expansion of the literature that addresses cognitive
issues in MS [25]. While the nature of this cognitive
dysfunction is relatively well described, prior studies of
the relationship between cognitive impairment and QoL
have been contradictory. To our knowledge, only one
recent study has described these links using both a stan-
dardised cognitive evaluation (BRB-N) and a specific
self-reported QoL questionnaire [16]. This work
enrolled only patients with early MS, and depression
was the only controlled parameter. Our study proposed
as i m i l a rs t u d yd e s i g nb u ti n c l u d e da l lM Ss u b t y p e sa n d
considered more key confounding factors. Consistent
with Glanz’s study [16], QoL was weakly or negligibly
related to cognitive function. The link of interest (con-
nection between visuospatial learning and the relation-
ship with health care systems) has not been described
elsewhere. This link did not seem substantial because
no robust clinical hypothesis supported or denied this
association.
L o v e r aa n dc o l l e a g u e sd i dn o tf i n dr e l a t i o n s h i p s
between attention or memory impairment and scores on
the Perceived Deficits Questionnaire, which is restricted
to assessment of self-perceived cognitive difficulties [11].
Rao found only non-significant trends between cognitive
impairment and QoL as assessed by a generic question-
naire, the Sickness Impact Profile [10]. In Montel’s
Table 2 Correlations between QoL (MusiQoL and SF36) and the BRB-N subtests, fatigue, and depression
MusiQoL
a SF36
b
ADL
a PWB
a RFr
a SPT
a RFa
a RHCS
a SSL
a COP
a REJ
a Index
a PCS
b MCS
b
SRT-L
c -0.04 -0.02 -0.15* 0.17* -0.08 -0.07 0.06 0.02 -0.22** -0.14* -0.07 -0.03
SRT-C
c -0.05 -0.08 -0.05 0.13* -0.04 -0.04 0.11 -0.03 -0.25** -0.08 -0.11 0.01
SRT-D
c 0.02 -0.15* -0.06 0.07 -0.02 -0.08 0.13* 0.02 -0.35*** -0.13* -0.007 -0.03
SPART-T
c -0.06 -0.01 0.12* 0.06 0.21** 0.08 0.33*** 0.18* -0.05 0.16* -0.19* 0.05
SPART-D
c -0.08 0.04 0.08 -0.06 0.22** -0.03 0.24** 0.21* -0.13* 0.06 -0.28*** 0.13*
SDMT
c 0.23** 0.01 -0.001 0.15* 0.05 -0.09 0.19* 0.16* -0.20* 0.07 0.07 0.11
PASAT-3
c 0.09 0.02 0.07 0.20** 0.06 0.09 0.16* 0.11 -0.26** 0.11 -0.003 0.23**
WLG
c 0.12* 0.11* 0.09 0.24** 0.02 -0.11* 0.16* 0.15* 0.001 0.17* 0.03 0.17*
MFIS-Ph
d -0.58*** -0.17* 0.22** -0.29*** 0.20** -0.08 0.02 -0.06 -0.21** -0.11 -0.61*** -0.25**
MFIS-Cg
d -0.29*** -0.28*** 0.05 -0.62*** -0.11* 0.05 -0.14* -0.12* -0.13* -0.35*** -0.17* -0.47***
MFIS-Ps
d -0.57*** -0.21** 0.02 -0.26*** 0.14* -0.24** -0.08 -0.27*** -0.28*** -0.40*** -0.52*** -0.34***
MFIS-To
d -0.55*** -0.30*** 0.11* -0.52*** 0.05 -0.07 -0.10 -0.17* -0.23** -0.34*** -0.47*** -0.44***
BDI
e -0.44*** -0.44*** -0.17* -0.23* -0.25** -0.18* -0.25* -0.27** -0.18* -0.53*** -0.32** -0.56***
aMusiQoL Multiple Sclerosis International Quality of Life, ADL activity of daily living, PWB psychological well-being, RFr relationships with friends, SPT symptoms,
RFa relationships with family, RHCS relationships with health care system, SSL sentimental and sexual life, COP coping, REJ rejection, Index global score.
bSF36 Short Form 36, PCS physical composite score, MCS mental composite score.
cSRT-L Selective Reminding Test Long-term, SRT-C Selective Reminding Test Consistent long-term, SRT-D Selective Reminding Test Delayed, SPART-T SPAtial Recall
Test Total, SPART-D SPAtial Recall Test Delayed, SDMT Symbol Digit Modalities Test, PASAT-3 Paced Auditory Serial Addition Test 3 s, WLG Word List Generation
test.
dMFIS-Ph Modified Fatigue Impact Scale physical, MFIS-Cg cognitive, MFIS-Ps psychosocial, MFIS-To total.
eBDI Beck Depression Inventory.
Spearman rank correlation coefficients were presented.
*p-value < 0.30, **p-value < 0.05, ***p-value < 0.01.
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Page 4 of 10Table 3 Associations between MusiQoL dimension scores and sociodemographics, clinical characteristics, and cognitive function
ADL
a PWB
a RFr
a SPT
a RFa
a RHCS
a SSL
a COP
a REJ
a Index
a
Gender*
Women 28.64 (21.36) 44.43 (26.21) 63.47 (24.36) 50.64 (24.70) 71.47 (26.54) 70.51 (18.23) 53.13 (31.49) 53.07 (29.99) 60.28 (34.96) 54.63 (11.88)
Men 31.72 (21.17) 59.68 (19.86) 60.20 (24.17) 59.29 (21.93) 73.14 (22.65) 68.14 (21.15) 44.21 (31.76) 59.30 (28.49) 73.89 (29.77) 59.28 (13.14)
p* 0.28 0.002 0.41 0.04 0.99 0.70 0.19 0.28 0.03 0.08
Educational level*
<12 years 27.93 (16.61) 48.78 (25.54) 62.08 (25.51) 49.90 (24.71) 71.17 (27.02) 73.84 (18.91) 47.84 (33.64) 53.29 (28.59) 64.73 (34.30) 55.76 (13.00)
≥ 12 years 32.25 (25.54) 53.49 (23.87) 61.98 (22.80) 59.49 (21.91) 73.37 (22.28) 64.30 (19.04) 50.91 (29.50) 58.51 (30.41) 67.40 (32.70) 57.78 (12.09)
p* 0.79 0.36 0.81 0.03 0.91 0.007 0.71 0.36 0.77 0.31
Marital status*
Single 31.04 (22.14) 50.00 (26.69) 56.25 (27.59) 51.73 (23.33) 63.30 (27.61) 65.30 (19.73) 34.89 (33.79) 52.88 (32.24) 65.50 (35.01) 52.53(14.44)
Married/partnership 28.94 (20.54) 51.81 (23.20) 66.73 (20.12) 56.60 (24.27) 79.86 (19.41) 73.13 (18.67) 59.09 (26.29) 58.41 (26.28) 69.32 (31.81) 59.57 (10.23)
p* 0.65 0.52 0.06 0.26 0.002 0.05 0.001 0.45 0.34 0.03
Living*
Personal home 30.65 (21.96) 52.97 (24.22) 63.32 (23.41) 54.89 (24.25) 71.76 (25.04) 70.03 (19.48) 49.38 (31.92) 58.52 (28.65) 68.27 (32.93) 57.33 (12.47)
Friend/family home 27.91 (15.04) 35.90 (24.39) 54.55 (30.36 48.88 (19.84) 69.23 (27.08) 65.38 (20.08) 28.57 (25.73) 41.34 (32.03) 58.65 (32.02) 51.46 (14.00)
p* 0.88 0.03 0.22 0.36 0.79 0.35 0.10 0.07 0.23 0.31
Occupational status*
Working 40.84 (22.53) 54.38 (26.65) 59.48 (23.12) 56.82 (24.19) 76.58 (25.35) 70.68 (20.33) 52.00 (30.34) 57.41 (27.13) 65.95 (31.32) 57.08 (14.44)
Not working 25.96 (19.20) 50.47 (23.83) 64.47 (24.35) 53.15 (24.19) 70.36 (25.01) 68.91 (19.43) 48.05 (33.13) 55.07 (30.61) 66.83 (33.80) 56.89 (11.95)
p* 0.001 0.57 0.20 0.52 0.20 0.58 0.62 0.76 0.80 0.80
MS subtype**
RR
b 39.33 (23.67) 48.61 (24.25) 59.31 (26.61) 48.11 (25.29) 65.53 (27.74) 75.39 (16.54) 44.64 (28.95) 62.90 (31.54) 62.10 (31.04) 56.59 (10.27)
PP
b 19.10 (16.39) 51.43 (22.59) 57.02 (25.80) 52.63 (21.18) 75.44 (23.28) 60.09 (23.50) 54.17 (36.49) 52.78 (23.70) 69.85 (37.00) 54.98 (16.88)
SP
b 25.61 (17.06) 51.76 (26.07) 65.20 (23.96) 57.75 (23.88) 73.03 (23.94) 69.52 (19.22) 48.37 (32.12) 51.56 (30.25) 67.55 (35.20) 56.56 (12.77)
CIS
b 50.52 (26.62) 59.72 (26.41) 63.89 (15.51) 67.71 (14.48) 86.11 (13.61) 66.67 (15.81) 70.83 (31.46) 58.33 (28.14) 62.50 (26.22) 64.77 (8.95)
p** 0.001 0.82 0.61 0.14 0.29 0.13 0.45 0.30 0.63 0.73
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0Table 3 Associations between MusiQoL dimension scores and sociodemographics, clinical characteristics, and cognitive function (Continued)
Cognitive function*
No deficit 31.03 (20.73) 52.08 (25.34) 61.42 (22.04) 58.22 (23.30) 74.27 (22.55) 67.26 (18.25) 52.55 (29.53) 59.72 (27.00) 63.39 (30.97) 57.10 (12.16)
Deficit 28.73 (22.53) 50.71 (24.13) 60.66 (26.65) 52.14 (26.00) 67.98 (28.81) 70.72 (20.45) 44.20 (36.08) 50.00 (32.57) 72.26 (36.44) 54.82 (14.14)
p* 0.34 0.86 1.00 0.25 0.42 0.36 0.31 0.15 0.11 0.68
EDSS
d*** -0.40 0.09 0.15 0.12 0.08 -0.12 0.10 -0.06 0.17 0.12
p 0.001 0.37 0.13 0.23 0.43 0.24 0.37 0.58 0.09 0.30
Disease duration*** -0.05 -0.07 0.08 0.03 -0.13 -0.04 0.05 0.03 0.10 0.06
p 0.59 0.48 0.45 0.76 0.16 0.68 0.64 0.80 0.32 0.56
Age*** -0.05 0.13 0.07 0.06 -0.07 0.06 -0.04 0.18 0.13 0.06
p 0.57 0.17 0.47 0.54 0.46 0.55 0.71 0.07 0.19 0.59
aADL activity of daily living, PWB psychological well-being, RFr relationships with friends, SPT symptoms, RFa relationships with family, RHCS relationships with health care system, SSL sentimental and sexual life, COP
coping, REJ rejection.
bRR Relapsing remitting, PP Primary progressive, SP Secondary progressive, CIS Clinically isolated syndrome.
cCognitive function is defined as a deficit from BRB-N with at least three of eight impaired subtests.
dEDSS Expanded Disability Status Scale.
* mean (standard deviation), p: p-value Mann-Whitney test.
** mean (standard deviation), p: p-value Kruskal-Wallis test.
*** Spearman’s correlation coefficient, p: p-value Spearman’s test.
Bold values: p < 0.05.
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0study, a negative impact of cognitive impairment
(defined by frontal lobe dysfunction) was identified only
in the context of the mental health limitations domain
of the SEP-59 questionnaire [12]. Mental and physical
health composites of the MSQOL-54 were not predicted
by cognitive functions in Benedict’s report [7]. Cognitive
status was not identified as a QoL predictive factor by
Amato et al. [13].
Other authors have reported a more obvious associa-
tion between cognitive deficits and self-reported out-
comes, including QoL. Gold and colleagues identified
lower QoL levels with the MS-specific Hamburg Quality
of Life Questionnaire in cognitively impaired patients
relative to cognitively preserved patients, but cognitive
impairment was defined with a single attention-memory
test (SDMT) [15]. In Miller’s study, correlations between
QoL (using generic questionnaires) and the Multiple
Sclerosis Functional Composite were described, but the
latter is not a strictly cognitive assessment tool but
instead includes two clinical dimensions [14]. Because
the MusiQoL is based on the concept of a health-related
quality of life measure, no strong correlations with cog-
nitive status are expected or sought. This result rein-
forces the validity and the acceptability of this
questionnaire and is consistent with studies reporting
that cognitively disabled patients are able to give
Table 4 Predictive factors for MusiQoL dimensions and index: multivariate analysis (standardised beta coefficient)
ADL
a PWB
a RFr
a SPT
a RFa
a RHCS
a SSL
a COP
a REJ
a Index
Gender (0 women, 1 men) b* -0.011 0.161 -0.563 -0.017 -0.036 -0.302 -0.416 0.329 0.285 0.026
p* 0.938 0.314 0.004 0.922 0.837 0.052 0.037 0.057 0.158 0.886
Marital status (0 single, 1 couple) b* -0.077 -0.015 0.421 0.075 0.459 0.722 0.261 -0.011 -0.013 0.526
p* 0.571 0.919 0.02 0.642 0.008 <10-3 0.130 0.944 0.945 0.007
CIS
b (0 PP
b) b* -0.312 -0.461 -0.106 -0.226 -0.087 -0.461 0.070 -0.345 -0.284 -0.309
p* 0.092 0.027 0.644 0.297 0.690 0.019 0.738 0.107 0.250 0.124
SP
b (0 PP
b) b* -0.013 -0.049 0.392 -0.158 0.182 -0.130 0.416 -0.112 0.135 0.127
p* 0.946 0.821 0.138 0.507 0.449 0.534 0.177 0.631 0.620 0.670
RR
b (0 PP
b) b* -0.389 -0.415 -0.037 -0.369 0.025 -0.654 0.285 -0.500 -0.271 -0.418
p* 0.067 0.077 0.890 0.140 0.922 0.004 0.317 0.043 0.325 0.117
Age b* 0.159 0.285 -0.368 0.363 -0.171 -0.045 -0.295 0.357 -0.004 -0.260
p* 0.246 0.064 0.056 0.030 0.299 0.750 0.105 0.029 0.980 0.132
EDSS
c b* -0.421 0.429 0.214 0.171 0.274 0.575 0.401 0.376 0.332 0.633
p* 0.027 0.038 0.360 0.436 0.214 0.005 0.084 0.085 0.190 0.006
Disease duration b* 0.361 -0.021 0.135 -0.071 -0.203 -0.360 -0.185 0.085 0.295 -0.182
p* 0.044 0.908 0.565 0.731 0.338 0.054 0.449 0.674 0.209 0.434
MFIS-To
d b* -0.324 -0.272 0.187 -0.680 0.113 0.373 -0.085 -0.023 -0.061 0.130
p* 0.043 0.117 0.353 0.001 0.550 0.027 0.670 0.896 0.770 0.493
BDI
e b* -0.142 -0.317 -0.115 0.318 -0.317 -0.116 -0.061 -0.343 -0.200 -0.413
p* 0.323 0.046 0.530 0.068 0.072 0.438 0.728 0.044 0.304 0.018
SRT-L
f b* -0.259 0.155 -0.433 -0.071 -0.194 -0.140 -0.456 0.071 0.202 -0.228
p* 0.152 0.431 0.069 0.739 0.343 0.452 0.068 0.732 0.401 0.276
SRT-D
f b* 0.121 -0.075 -0.171 0.181 -0.009 -0.210 0.155 0.133 -0.208 0.035
p* 0.482 0.692 0.439 0.378 0.965 0.246 0.518 0.507 0.366 0.864
SPART-T
f b* 0.014 0.184 -0.086 0.034 -0.005 -0.429 0.004 0.307 0.120 -0.152
p* 0.928 0.270 0.667 0.852 0.977 0.010 0.983 0.087 0.552 0.413
WLG
f b* 0.244 0.072 0.196 0.220 -0.167 -0.100 0.392 -0.042 -0.023 0.078
p* 0.084 0.640 0.301 0.186 0.312 0.489 0.056 0.795 0.902 0.666
aADL activity of daily living, PWB psychological well-being, RFr relationships with friends, SPT symptoms, RFa relationships with family, RHCS relationships with
health care system, SSL sentimental and sexual life, COP coping, REJ rejection.
bRR Relapsing remitting, PP Primary progressive, SP Secondary progressive, CIS Clinically isolated syndrome.
cEDSS Expanded Disability Status Scale.
dMFIS-To Modified Fatigue Impact Scale total.
eBDI Beck Depression Inventory.
fSRT-L Selective Reminding Test Long-term, SRT-D Selective Reminding Test Delayed, SPART-T SPAtial Recall Test Total, WLG Word List Generation test.
*b: standardised beta coefficient (b represents the change of the standard deviation in QoL score resulting from a change of one standard deviation in the
independent variable); p: p-value.
Bold values: p < 0.05.
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Page 7 of 10consistent answers to questionnaires [15]. Finally,
Benito-Leon’s study reported associations between lower
cognitive scores (MMSE) and lower QoL levels (Func-
tional Assessment of MS) [5].
The existing data regarding factors that predict QoL
in MS cases is somewhat contradictory. We found that
gender was not linked to the global QoL score, as
reported elsewhere [5,7,22,26]; other authors have
shown that women with MS reported poorer QoL than
m e n[ 2 7 ] .O nt h eo t h e rh a n d ,w o m e nr e p o r t e dw o r s e
QoL than men for dimensions such as coping and rejec-
t i o n ,s u g g e s t i n gt h a tw o m e nm a yb em o r ev u l n e r a b l e ,
and a higher QoL for relationships with friends and sen-
timental life. Similarly, subjects in a relationship
described a higher QoL than single individuals in the
MusiQoL index and in three dimensions (friends, family
and health care relationships), though this association is
not always found [28].
The disability level influenced a subset of QoL
aspects, but the direction of this effect varied. Consis-
tent with previous works, high disability was related to
poorer QoL related to activities of daily living. Patients
with higher disability, defined either by EDSS [6,7] or
by other clinical rating scales [29], revealed signifi-
cantly worse QoL than those with less pronounced dis-
abilities. Conversely, severe disability was associated
with better global QoL scores and a higher score in
the psychological well-being and health care relation-
ships dimensions, suggesting the potential relevance of
coping strategies [30]. These weak and contradictory
relationships between disability and QoL [8] confirm
that clinical assessment does not reflect all the aspects
that patients consider important in their life. We are
reminded of the need to use a multi-dimensional
approach for QoL assessment [31]. Disease duration
was poorly associated with some QoL aspects, as
already described [32]. Age is not related to QoL, but
the literature reports contradictory results with either
poorer [33] or better QoL [34] in older MS subjects.
Finally, the strong influence of depression and fatigue
as independent predictors of some aspects of QoL in
MS patients was confirmed [8,11,35]. These parameters
may be of significant clinical value for health care
workers. Indeed, they can detect, prevent, or manage
depression or fatigue possibly impacting QoL for MS
patients. Our small sample size did not allow us to
identify other factors predictive of QoL that have been
reported elsewhere. We were unable to confirm the
impact of anxiety [36] because this data was not col-
lected in our study.
We note several strengths and limitations of this
study:
1) The sample size was arguably too small. When we
tried to identify linked factors using the multivariate
approach, moderate associations may have been missed
due to low statistical power. Nevertheless, the literature
includes several studies with similar or smaller sample
sizes [7,11,12].
2) The representativeness of our sample should be
questioned. Compared to the international and Eur-
opean MS populations [22,37], our patients had a higher
sex-ratio (0.41 and 0.60, respectively), a more severe dis-
ability profile (EDSS median 3.2 and 4.1, respectively),
and a higher proportion of secondary progressive MS
(21% and 36%, respectively). These disparities may par-
tially explain the lower QoL scores reported by this
population compared to others.
3) We are concerned about our neurocognitive assess-
ment approach using BRB-N. Two neuropsychological
batteries have been well-validated. The BRB-N and the
MACFIMS [38] have comparable sensitivity among MS
patients [39]. We chose to use the BRB-N because it
was the most widely used at the beginning of this study.
However, the BRB-N has several notable disadvantages:
i) most studies have used a limited number of subtests
from the complete set, and these truncated results are
not readily comparable with studies that use the com-
plete battery; ii) the executive function evaluation is not
satisfactory; iii) the test performance requires fine visual
acuity or motor speed.
4) There is no consensus on the definition of cognitive
impairment, as underlined by Achiron and Barak [40].
Many studies define the cognitive impairment of a MS
sample in comparison to a control group, while other
studies use available normative values. Our choice of
European norms [24], defined from a sample that
included European populations, is questionable. Alterna-
tive normative values have been defined in Dutch [41],
Italian [42], and Spanish [43] populations. French norms
were proposed by Dujardin et al. [44], but their version
differed from the standard BRB-N in terms of the con-
tent and the number of subtests. Furthermore, a patient
may be considered cognitively impaired for one test if
the score is less than 2 SDs [45,46], less than 1.5 SDs
[47,48], or less than the fifth percentile [49] of healthy
controls. A patient can be considered cognitively
impaired for a global battery in the case of at least three
impaired tests [24,46,50], or two impaired tests [49], or
even just one impaired test [45]. The proportion of cog-
nitively impaired patients depended on these definitions.
These disparities make comparisons difficult between
studies.
5) We did not assess thoroughly cognitive QoL nor
specific cognitive dysfunction on daily functioning.
Further studies should try to disentangle the impact of
different cognitive domains on cognitive QoL on one
hand and on cognitive daily functioning on the other
hand.
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Although cognitive impairment is an important symp-
tom in MS, its relationship with QoL appears to be con-
tradictory. The present study, using a standardised
neuropsychological battery and a disease-specific
patient-based instrument, demonstrated the weak and
scarce associations between cognitive disturbances and
QoL alterations when confounding factors were
accounted for. These preliminary results need to be con-
firmed with larger samples using more accurate tests of
cognitive function.
Acknowledgements
We are grateful to all the patients for their participation in the study. This
work was supported by institutional grants from the French 2004
Programme Hospitalier Recherche Clinique, and the sponsor was
represented by Assistance Publique, Hôpitaux de Marseille. The manuscript
was edited by native English-speaking editors at American Journal Experts
(Key: F1CF-4A4F-1469-BD07-46A7).
Author details
1EA3279 Self-perceived Health Assessment Research Unit and Department of
Public Health, Nord University Hospital, APHM, Marseille, France.
2Departments of Neurology and CRMBM CNRS6612, Timone University
Hospital, APHM, Marseille, France.
3EA 3273 Psychology of Cognition,
Language, and Emotion Research Centre, Aix-Marseille University, France.
Authors’ contributions
Conception and design: PA, JP, MCS. Study coordination: PA, JP, KBB.
Inclusion and clinical data collection: IK, JP. Acquisition of cognitive data: FR,
VA. Analysis of data: KBB. Interpretation of data: KBB, PA, JP, FR, VA. Drafting
and writing of manuscript: KBB, PA. Revision of manuscript: PA, JP, FR, MCS,
VA, IK.
All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 28 July 2010 Accepted: 2 February 2011
Published: 2 February 2011
References
1. Amato MP, Zipoli V, Portaccio E: Multiple sclerosis-related cognitive
changes: a review of cross-sectional and longitudinal studies. J Neurol Sci
2006, 245:41-46.
2. Goverover Y, Chiaravalloti N, DeLuca J: The relationship between self-
awareness of neurobehavioral symptoms, cognitive functioning, and
emotional symptoms in multiple sclerosis. Mult Scler 2005,
11:203-212.
3. Feuillet L, Reuter F, Audoin B, Malikova I, Barrau K, Cherif AA, Pelletier J:
Early cognitive impairment in patients with clinically isolated syndrome
suggestive of multiple sclerosis. Mult Scler 2007, 13:124-127.
4. Achiron A, Barak Y: Cognitive impairment in probable multiple sclerosis. J
Neurol Neurosurg Psychiatry 2003, 74:443-446.
5. Benito-Leon J, Morales JM, Rivera-Navarro J: Health-related quality of life
and its relationship to cognitive and emotional functioning in multiple
sclerosis patients. Eur J Neurol 2002, 9:497-502.
6. Miller DM, Rudick RA, Baier M, Cutter G, Doughtery DS, Weinstock-
Guttman B, Mass MK, Fisher E, Simonian N: Factors that predict health-
related quality of life in patients with relapsing-remitting multiple
sclerosis. Mult Scler 2003, 9:1-5.
7. Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F,
Zivadinov R, Weinstock-Guttman B: Predicting quality of life in
multiple sclerosis: accounting for physical disability, fatigue,
cognition, mood disorder, personality, and behavior change.
JN e u r o lS c i2005, 231:29-34.
8. Mitchell AJ, Benito-Leon J, Gonzalez JM, Rivera-Navarro J: Quality of life
and its assessment in multiple sclerosis: integrating physical and
psychological components of wellbeing. Lancet Neurol 2005, 4:556-566.
9. Rudick RA, Miller DM: Health-related quality of life in multiple sclerosis:
current evidence, measurement and effects of disease severity and
treatment. CNS Drugs 2008, 22:827-839.
10. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F: Cognitive
dysfunction in multiple sclerosis. II. Impact on employment and social
functioning. Neurology 1991, 41:692-696.
11. Lovera J, Bagert B, Smoot KH, Wild K, Frank R, Bogardus K, Oken BS,
Whitham RH, Bourdette DN: Correlations of Perceived Deficits
Questionnaire of Multiple Sclerosis Quality of Life Inventory with Beck
Depression Inventory and neuropsychological tests. J Rehabil Res Dev
2006, 43:73-82.
12. Montel SR, Bungener C: Coping and quality of life in one hundred and
thirty five subjects with multiple sclerosis. Mult Scler 2007, 13:393-401.
13. Amato MP, Ponziani G, Siracusa G, Sorbi S: Cognitive dysfunction in early-
onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol 2001,
58:1602-1606.
14. Miller DM, Rudick RA, Cutter G, Baier M, Fischer JS: Clinical significance of
the multiple sclerosis functional composite: relationship to patient-
reported quality of life. Arch Neurol 2000, 57:1319-1324.
15. Gold SM, Schulz H, Monch A, Schulz KH, Heesen C: Cognitive impairment
in multiple sclerosis does not affect reliability and validity of self-report
health measures. Mult Scler 2003, 9:404-410.
16. Glanz BI, Healy BC, Rintell DJ, Jaffin SK, Bakshi R, Weiner HL: The association
between cognitive impairment and quality of life in patients with early
multiple sclerosis. J Neurol Sci 2009, 290:75-79.
17. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD,
McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M,
Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS:
Recommended diagnostic criteria for multiple sclerosis: guidelines from
the International Panel on the diagnosis of multiple sclerosis. Ann Neurol
2001, 50:121-127.
18. Polman CH, Wolinsky JS, Reingold SC: Multiple sclerosis diagnostic criteria:
three years later. Mult Scler 2005, 11:5-12.
19. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for
measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
20. Kos D, Kerckhofs E, Carrea I, Verza R, Ramos M, Jansa J: Evaluation of the
Modified Fatigue Impact Scale in four different European countries. Mult
Scler 2005, 11:76-80.
21. Leplege A, Ecosse E, Verdier A, Perneger TV: The French SF-36 Health
Survey: translation, cultural adaptation and preliminary psychometric
evaluation. J Clin Epidemiol 1998, 51:1013-1023.
22. Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S,
Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N,
O’Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S,
Ammoury N, Beresniak A, Pelletier J: Validation of the Multiple Sclerosis
International Quality of Life questionnaire. Mult Scler 2008, 14:219-230.
23. Rao SM, the Cognitive Function Study Group of the National Multiple
Sclerosis Society: A manual for the Brief Repeatable Battery of
Neuropsychological Tests in multiple sclerosis Milwaukee: Medical College of
Wisconsin; 1990.
24. Camp SJ, Stevenson VL, Thompson AJ, Miller DH, Borras C, Auriacombe S,
Brochet B, Falautano M, Filippi M, Herisse-Dulo L, Montalban X, Parrcira E,
Polman CH, De Sa J, Langdon DW: Cognitive function in primary
progressive and transitional progressive multiple sclerosis: a controlled
study with MRI correlates. Brain 1999, 122(Pt 7):1341-1348.
25. Bobholz JA, Rao SM: Cognitive dysfunction in multiple sclerosis: a review
of recent developments. Curr Opin Neurol 2003, 16:283-288.
26. Krokavcova M, Nagyova I, van Dijk JP, Rosenberger J, Gavelova M, Middel B,
Gdovinova Z, Groothoff JW: Mastery, functional disability and perceived
health status in patients with multiple sclerosis. Eur J Neurol 2008,
15:1237-1244.
27. Hopman WM, Harrison MB, Coo H, Friedberg E, Buchanan M,
Vandenkerkhof EG: Associations between chronic disease, age and
physical and mental health status. Chronic Dis Can 2009, 29:108-116.
28. Pekmezovic T, Kisic Tepavcevic D, Kostic J, Drulovic J: Validation and cross-
cultural adaptation of the disease-specific questionnaire MSQOL-54 in
Serbian multiple sclerosis patients sample. Qual Life Res 2007,
16:1383-1387.
Baumstarck-Barrau et al. BMC Neurology 2011, 11:17
http://www.biomedcentral.com/1471-2377/11/17
Page 9 of 1029. Yozbatiran N, Baskurt F, Baskurt Z, Ozakbas S, Idiman E: Motor assessment
of upper extremity function and its relation with fatigue, cognitive
function and quality of life in multiple sclerosis patients. J Neurol Sci
2006, 246:117-122.
30. McCabe MP, Stokes M, McDonald E: Changes in quality of life and coping
among people with multiple sclerosis over a 2 year period. Psychol
Health Med 2009, 14:86-96.
31. Patrick DL, Erikson P: Health status and health policy: allocating resources to
health care New York: Oxford University Press; 1993.
32. Marrie RA, Miller DM, Chelune GJ, Cohen JA: Validity and reliability of the
MSQLI in cognitively impaired patients with multiple sclerosis. Mult Scler
2003, 9:621-626.
33. Turpin KV, Carroll LJ, Cassidy JD, Hader WJ: Deterioration in the health-
related quality of life of persons with multiple sclerosis: the possible
warning signs. Mult Scler 2007, 13:1038-1045.
34. Dilorenzo TA, Halper J, Ann Picone M: Quality of life in MS: Does aging
enhance perceptions of mental health? Disabil Rehabil 2009, 1-8.
35. Janardhan V, Bakshi R: Quality of life in patients with multiple sclerosis:
the impact of fatigue and depression. J Neurol Sci 2002, 205:51-58.
36. Janssens AC, van Doorn PA, de Boer JB, Kalkers NF, van der Meche FG,
Passchier J, Hintzen RQ: Anxiety and depression influence the relation
between disability status and quality of life in multiple sclerosis. Mult
Scler 2003, 9:397-403.
37. Amato MP, Grimaud J, Achiti I, Bartolozzi ML, Adeleine P, Hartung HP,
Kappos L, Thompson A, Trojano M, Vukusic S, Confavreux C: European
validation of a standardized clinical description of multiple sclerosis.
J Neurol 2004, 251:1472-1480.
38. Benedict RH, Fischer JS, Archibald CJ, Arnett PA, Beatty WW, Bobholz J,
Chelune GJ, Fisk JD, Langdon DW, Caruso L, Foley F, LaRocca NG, Vowels L,
Weinstein A, DeLuca J, Rao SM, Munschauer F: Minimal
neuropsychological assessment of MS patients: a consensus approach.
Clin Neuropsychol 2002, 16:381-397.
39. Strober L, Englert J, Munschauer F, Weinstock-Guttman B, Rao S,
Benedict RH: Sensitivity of conventional memory tests in multiple
sclerosis: comparing the Rao Brief Repeatable Neuropsychological
Battery and the Minimal Assessment of Cognitive Function in MS. Mult
Scler 2009, 15:1077-1084.
40. Achiron A, Barak Y: Cognitive changes in early MS: a call for a common
framework. J Neurol Sci 2006, 245:47-51.
41. Boringa JB, Lazeron RH, Reuling IE, Ader HJ, Pfennings L, Lindeboom J, de
Sonneville LM, Kalkers NF, Polman CH: The brief repeatable battery of
neuropsychological tests: normative values allow application in multiple
sclerosis clinical practice. Mult Scler 2001, 7:263-267.
42. Amato MP, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro MF, Patti F,
Vecchio R, Sorbi S, Trojano M: The Rao’s Brief Repeatable Battery and
Stroop Test: normative values with age, education and gender
corrections in an Italian population. Mult Scler 2006, 12:787-793.
43. Sepulcre J, Vanotti S, Hernandez R, Sandoval G, Caceres F, Garcea O,
Villoslada P: Cognitive impairment in patients with multiple sclerosis
using the Brief Repeatable Battery-Neuropsychology test. Mult Scler 2006,
12:187-195.
44. Dujardin K, Sockeel P, Cabaret M, De Seze J, Vermersch P: [BCcogSEP: a
French test battery evaluating cognitive functions in multiple sclerosis].
Rev Neurol (Paris) 2004, 160:51-62.
45. Blanc F, Zephir H, Lebrun C, Labauge P, Castelnovo G, Fleury M, Sellal F,
Tranchant C, Dujardin K, Vermersch P, de Seze J: Cognitive functions in
neuromyelitis optica. Arch Neurol 2008, 65:84-88.
46. Camp SJ, Stevenson VL, Thompson AJ, Ingle GT, Miller DH, Borras C,
Brochet B, Dousset V, Falautano M, Filippi M, Kalkers NF, Montalban X,
Polman CH, Langdon DW: A longitudinal study of cognition in primary
progressive multiple sclerosis. Brain 2005, 128:2891-2898.
47. Bobholz JA, Rao SM, Lobeck L, Elsinger C, Gleason A, Kanz J, Durgerian S,
Maas E: fMRI study of episodic memory in relapsing-remitting MS:
correlation with T2 lesion volume. Neurology 2006, 67:1640-1645.
48. Duque B, Sepulcre J, Bejarano B, Samaranch L, Pastor P, Villoslada P:
Memory decline evolves independently of disease activity in MS. Mult
Scler 2008, 14:947-953.
49. Deloire MS, Bonnet MC, Salort E, Arimone Y, Boudineau M, Petry KG,
Brochet B: How to detect cognitive dysfunction at early stages of
multiple sclerosis? Mult Scler 2006, 12:445-452.
50. Potagas C, Giogkaraki E, Koutsis G, Mandellos D, Tsirempolou E, Sfagos C,
Vassilopoulos D: Cognitive impairment in different MS subtypes and
clinically isolated syndromes. J Neurol Sci 2008, 267:100-106.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2377/11/17/prepub
doi:10.1186/1471-2377-11-17
Cite this article as: Baumstarck-Barrau et al.: Cognitive function and
quality of life in multiple sclerosis patients: a cross-sectional study. BMC
Neurology 2011 11:17.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Baumstarck-Barrau et al. BMC Neurology 2011, 11:17
http://www.biomedcentral.com/1471-2377/11/17
Page 10 of 10